Takeda to Develop Finch's Microbiome Therapeutic for IBD

Takeda to Develop Finch's Microbiome Therapeutic for IBD

Takeda is paying Finch Therapeutics $10 million upfront for exclusive, global rights to develop and commercialize the latter’s inflammatory bowel disease (IBD) candidate, FIN-524, together with rights to follow-on products for IBD indications.

Takeda partners with an upstart drugs-from-bugs microbiome player inspired by a fecal transplantation biz

Takeda partners with an upstart drugs-from-bugs microbiome player inspired by a fecal transplantation biz

Back when Mark Smith was working on his PhD at MIT about 6 years ago, his girlfriend’s cousin was infected with C.diff. After 7 reoccurrences following treatment with vancomycin, though, the cousin finally beat it by getting a fecal transplant, with his roommate as the donor.